Procore signs multi-year strategic collaboration agreement with AWS
David Moatazedi, President and CEO of Evolus, Inc. (NASDAQ:EOLS), a $760 million market cap healthcare company that has shown strong revenue growth of 32% over the last twelve months, has recently sold a portion of his holdings in the company. According to InvestingPro analysis, the stock appears undervalued despite a recent 7.5% decline over the past week. According to a filing with the Securities and Exchange Commission, Moatazedi sold 6,251 shares of Evolus common stock on March 27, 2025, at a price of $12.40 per share, totaling $77,512.
The transaction was conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stock, typically to avoid potential accusations of insider trading. The filing notes that the sale was made to cover tax withholding obligations related to the vesting of certain Restricted Stock Units.
Following this transaction, Moatazedi retains ownership of 508,619 shares of Evolus.
In other recent news, Evolus Inc . reported fourth-quarter 2024 financial results, highlighting a revenue of $79 million, which exceeded market expectations of $76.96 million, despite missing earnings per share (EPS) estimates with a reported EPS of -$0.11 against a forecasted $0.02. For the full year 2024, Evolus achieved global net revenues of $266.3 million, marking a 32% year-over-year increase. The company has provided guidance for 2025, projecting revenues between $345 million to $355 million, which would represent a 30% to 33% growth from 2024 figures. This optimistic outlook is supported by the early approval of new products, Evolysse SMOOTH and FORM, expected to contribute 8-10% of the total revenue for the fiscal year 2025.
Analysts from Stifel and H.C. Wainwright maintained their Buy ratings on Evolus stock, with price targets set at $25 and $27, respectively, reflecting confidence in the company’s future growth trajectory. Evolus’s strong performance in the fourth quarter also led to the company achieving full-year profitability ahead of schedule, with a positive non-GAAP operating income of $0.3 million for 2024. The company’s market share in the U.S. aesthetic toxin category has been expanding, with significant growth in active accounts and record enrollment in its loyalty programs.
Evolus’s leadership emphasized the significance of the FDA approval for Evolysse products, which is expected to drive future growth and expand the company’s total addressable market in the U.S. by 78%. The company aims for $700 million in revenue by 2028, with a target of a 20% non-GAAP operating income margin.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.